Descripción del proyecto
Una red de formación sobre vacunas está combatiendo simultáneamente la resistencia bacteriana y de la sociedad
La resistencia antimicrobiana ha adquirido unas proporciones pandémicas. Simultáneamente, un número cada vez mayor de personas se han vuelto reticentes a la vacunación. Cada vez se pide más a los científicos que defiendan todo tipo de problemas de la sociedad y que entren en escena en lugar de vestir batas blancas en laboratorios aislados con un contacto mínimo con el público. BactiVax se propone hacer justamente esto. Este proyecto está abordando todo el proceso de desarrollo de vacunas para infecciones bacterianas, que va desde el descubrimiento del antígeno hasta la administración de la vacuna. Sin embargo, su repercusión no quedará en el avance científico. El equipo ha adoptado la participación y concienciación del público como un pilar fundamental, y la defensa científica y la promoción pública estarán en manos de investigadores noveles, así como parte de la red de formación en vacunas bacterianas.
Objetivo
BactiVax (anti-Bacterial Innovative Vaccine Training Network) is a European training network (ETN) that will provide high-level training in vaccinology to a new generation of 15 high-achieving, early-stage researchers (ESRs). This innovative ETN uniquely blends cutting-edge research training, non-academic placements and transferable skills. It will develop strong entrepreneurial and creative mindsets. BactiVax will train ESRs in a broad range of transferable skills enabling them to thrive in careers in vaccine research within academia and/or industry through discovery, development, and delivery of innovative therapeutic and prophylactic vaccines. The World Health Organisation has identified antimicrobial resistance (AMR) as one of the three greatest threats to mankind. There is a urgent need to train innovative ESRs in the development of new vaccines against AMR infections. BactiVax will tackle the societal challenge caused by the emergence of AMR pathogens and have significant impact on pathogens causing chronic, life-threatening respiratory and/or systemic infections. BactiVax training will cover critical areas of vaccinology from early antigen discovery to optimisation of host response and delivery of vaccine antigens. It will also encompass the increasing problem of vaccine hesitancy in its public engagement. The specific research objectives are to: 1) Identify novel, protective vaccine antigens against target pathogens; 2) Optimise the host response to vaccines; 3) Optimise vaccine delivery; 4) Lead on vaccine advocacy. BactiVax includes 2 SME beneficiaries, a multinational vaccine company and 4 SMEs as partners all of whom are involved in training, entrepreneurship, commercial vaccine development and vaccine antigen processing. All ESRs will have secondments in non-academic environment to enhance their exposure to the commercial. Overall, BactiVax will provide ESRs with rich experience and advanced multidisciplinary skills in the cutting edge area of vaccines
Ámbito científico
Palabras clave
Programa(s)
Régimen de financiación
MSCA-ITN - Marie Skłodowska-Curie Innovative Training Networks (ITN)Coordinador
4 Dublin
Irlanda